Protective effect of Guanxinning on antipsychotic-induced cardiac impairment in long-term hospitalized psychiatric patients

Table 1 Evaluation indicators and measurement methods

Categories	Metrics	Measurement methods	Measuring frequency
ECG parameters	QT interval, QTc interval	A 12-lead ECG	Baseline, 12 months
An echocardiogram	LVEF, LVEDD, E/A ratio	Transthoracic echocardiography	Baseline, 12 months
Serum biomarkers	cTnI, BNP, NT-proBNP	Chemiluminescence immunoassay	Baseline, 12 months
Oxidative stress markers	SOD, MDA, GSH-Px	Spectrophotometry	Baseline, 12 months
Inflammatory markers	Hs-CRP, IL-6, TNF-α	ELISA	Baseline, 12 months
Metabolic measures	Fasting blood glucose, lipid profile, HbA1c	Automatic biochemical analyzer	Baseline, 12 months
Psychiatric symptoms	PANSS score	Scale assessment	Baseline, 12 months

ECG: Electrocardiography; QT: The time from the start of the Q wave to the end of the T wave; QTc: Corrected QT; LVEF: Left ventricular ejection fraction; LVEDD: Left ventricular end-diastolic diameter; E/A ratio: Early maximal ventricular filling velocity/atrial maximal ventricular filling velocity; cTnI: Cardiac troponin I; BNP: B-type natriuretic peptide; NT-proBNP: High N-terminal pro-B-type natriuretic peptide; SOD: Superoxide dismutase; MDA: Malondialdehyde; GSH-Px: Glutathione peroxidase; Hs-CRP: High-sensitivity C-reactive protein; IL-6: Interleukin-6; TNF-α: Tumor necrosis factor-alpha; HbA1c: Hemoglobin A1c; PANSS: Positive and negative syndrome score; ELISA: Enzyme linked immuno sorbent assay.